Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex
Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study
PaperCitations, authors & open-access status
Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 591 citations, 2020 year and closed oa status.
591
Citations
2020
Year
closed
OA Status